Uniqure NV

NASDAQ QURE

Data sourced from

and

Download Data

Uniqure NV Debt to Income Ratio 1 year YoY Change (%) for the quarter ending March 31, 2024: -16.84%

Uniqure NV Debt to Income Ratio 1 year YoY Change (%) is -16.84% for the quarter ending March 31, 2024, a -144.97% change year over year. The debt to income ratio measures the level of debt relative to a company's net income. It is calculated by dividing total debt by net income. This ratio provides insights into the company's ability to generate sufficient income to cover its debt obligations. A higher ratio indicates a higher level of debt burden relative to the company's income. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Uniqure NV Debt to Income Ratio for the quarter ending March 31, 2023 was -1.44, a 37.44% change year over year.
Uniqure NV Debt to Income Ratio for the quarter ending March 31, 2022 was -2.30, a -25.67% change year over year.
Uniqure NV Debt to Income Ratio for the quarter ending March 31, 2021 was -1.83, a -21.48% change year over year.
Uniqure NV Debt to Income Ratio for the quarter ending March 31, 2020 was -1.50, a -5.91% change year over year.

NASDAQ: QURE

Uniqure NV

CEO	Mr. Matthew Craig Kapusta
IPO Date	June 20, 2007
Location	Netherlands
Headquarters	Paasheuvelweg 25a, Amsterdam, Netherlands, 1105 BP
Employees	480
Sector	Healthcare
Industry	Biotechnology

Description

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Key trends